Selected references - TheraSorb® immunoadsorption

Discover the therapeutic potential of TheraSorb immunoadsorption – Explore selected publications in this reference list.
TheraSorb® – Ig omni 5 adsorber for immunoadsorption treatment
TheraSorb® – Ig omni 5 adsorber for immunoadsorption treatment
Logo

Selected references - TheraSorb® immunoadsorption

The TheraSorb adsorber for pan-Ig immunoadsorption has evolved over time. As shown in the illustration, changes have been made, for example, from glass to plastic housings, or from polyclonal antibody ligands to recombinant ligands.

The different adsorber generations are considered equivalent according to the equivalence criteria set out in the Medical Device Regulation (EU) 2017/745.

Therefore, the reference list below includes publications for the current generation of Ig omni adsorbers and for the predecessor generations. For each publication, it is indicated which adsorber generation was used in the underlying studies.

First Ig Therasorb adsorber is shown with info on glass housing and polyclonal antibody ligand.

Ig - TheraSorb

1996–2014
• 100 mL• Multiple use (up to 20 times for the same patient)
First Ig Therasorb adsorber is shown with info on glass housing and polyclonal antibody ligand.

Ig - TheraSorb

1996–2014
• 100 mL• Multiple use (up to 20 times for the same patient)
Therasorb Ig flex adsorber is shown with info on plastic housing and polyclonal antibody ligand

TheraSorb - Ig flex

2008–2020
• 50 mL• Multiple use (up to 10 times for the same patient)
Therasorb Ig flex adsorber is shown with info on plastic housing and polyclonal antibody ligand

TheraSorb - Ig flex

2008–2020
• 50 mL• Multiple use (up to 10 times for the same patient)

TheraSorb - Ig pro

2014–2020
• 100 mL• Multiple use (up to 20 times for the same patient)

TheraSorb - Ig pro

2014–2020
• 100 mL• Multiple use (up to 20 times for the same patient)
Therasorb Ig omni 1 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 1

Since 2016
• 50 mL
• Single use only
Therasorb Ig omni 1 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 1

Since 2016
• 50 mL
• Single use only
Therasorb Ig omni 5 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 5

Since 2016
• 100 mL• Multiple use (up to five times for the same patient)
Therasorb Ig omni 5 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 5

Since 2016
• 100 mL• Multiple use (up to five times for the same patient)
First Ig Therasorb adsorber is shown with info on glass housing and polyclonal antibody ligand.

Ig - TheraSorb

1996–2014
• 100 mL• Multiple use (up to 20 times for the same patient)
First Ig Therasorb adsorber is shown with info on glass housing and polyclonal antibody ligand.

Ig - TheraSorb

1996–2014
• 100 mL• Multiple use (up to 20 times for the same patient)
Therasorb Ig flex adsorber is shown with info on plastic housing and polyclonal antibody ligand

TheraSorb - Ig flex

2008–2020
• 50 mL• Multiple use (up to 10 times for the same patient)
Therasorb Ig flex adsorber is shown with info on plastic housing and polyclonal antibody ligand

TheraSorb - Ig flex

2008–2020
• 50 mL• Multiple use (up to 10 times for the same patient)

TheraSorb - Ig pro

2014–2020
• 100 mL• Multiple use (up to 20 times for the same patient)

TheraSorb - Ig pro

2014–2020
• 100 mL• Multiple use (up to 20 times for the same patient)
Therasorb Ig omni 1 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 1

Since 2016
• 50 mL
• Single use only
Therasorb Ig omni 1 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 1

Since 2016
• 50 mL
• Single use only
Therasorb Ig omni 5 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 5

Since 2016
• 100 mL• Multiple use (up to five times for the same patient)
Therasorb Ig omni 5 adsorber is shown with info on plastic housing and recombinant ligand

TheraSorb - Ig omni 5

Since 2016
• 100 mL• Multiple use (up to five times for the same patient)

Discover selected references

Guidelines on immunoadsorption

  • Standard der therapeutischen Apherese 2023
    Deutsche Gesellschaft für Nephrologie e.V. et al. (2023) | Accessed March 2025 | Visit website

  • Guidelines on the use of therapeutic apheresis in clinical practice – Evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue
    Connelly-Smith, L. et al. (2023) J. Clin. Apher. 38: 277–278. | Read article

General aspects of therapeutic apheresis

  • Immunoadsorption and plasmapheresis at the ICU – A description of the frequencies and indications in a single center experience and a case report
    Koball, S. et al. (2022) Ther. Apher. Dial. 26 (suppl. 1): 97–101. | Read article | TheraSorb - Ig pro

  • Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins
    Tselmin, S. et al. (2017) Atheroscler. Suppl. 30: 278–282. | Read article | Ig - TheraSorb, TheraSorb - Ig pro, TheraSorb - Ig flex

  • Immunoadsorption (IAS) „matures“
    Derfler, K. and Druml, W. (2004) Wien klein. Wochenschr. 116: 699–702. | Read article | Ig - TheraSorb

  • Immunoadsorption and plasma exchange in pregnancy
    Dittrich, E. et al. (2002) Kidney Blood Press. Res. 25: 232–239. | Read article | Ig - TheraSorb

  • Influence of plasma immunoglobulin level on antibody synthesis
    Goldammer, A. et al. (2002) Blood 100: 353–355. | Read article | Ig - TheraSorb

  • Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?
    Schmaldienst, S. et al. (2001) Rheumatology 40: 513–521. | Read article | Ig - TheraSorb

  • Local anticoagulation of the extracorporeal circuit with heparin and subsequent neutralization with protamine during immunoadsorption
    Schmaldienst, S. et al. (2000) Am. J. Kidney Dis. 36: 490–497. | Read article | Ig - TheraSorb

  • Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins
    Koll, R. A. (1998) Ther. Apher. 2: 147–152. | Read article | Ig - TheraSorb

  • Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy
    Schneider, K. M. (1998) Kidney Int. Suppl. 64: S61–5. | Read article | Ig - TheraSorb

  • Efficacy and safety of immunoglobulin apheresis
    Richter, W. O. et al. (1997) Asaio. J. 43: 53–9. | Read article | Ig - TheraSorb

COVID, long/post COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

  • Immunoadsorption as a method of antibody donation during the COVID-19 pandemic
    Rothenburg, J. et al. (2025) Vox Sang. 119: 792–800. | Read article | TheraSorb - Ig flex, TheraSorb - Ig omni 1

  • Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and/or aggravated ME/CFS
    Anft, M. et al. (2025) Mol. Ther. Jan 10: S1525–0016(25)00011-5. Epub ahead of print. | Read article | TheraSorb - Ig omni 5

  • Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study
    Stein, E. et al. (2024) Lancet Reg. Health Eur. 49: 101161 | Read article | TheraSorb - Ig omni 5

  • Immune adsorption for the treatment of fatigue-dominant long-/post-COVID syndrome: A series of cases with standardized individual experimental therapy
    Ruhe, J. et al. (2023) Dtsch. Arztebl. Int. 120: 499–500. | Read article | TheraSorb - Ig omni 5

  • Observational study of repeat immunoadsorption (RIA) in post-COVID ME/CFS patients with elevated ß2-adrenergic receptor autoantibodies - an interim report
    Stein, E. et al. (2023) J. Clin. Med. 12: 6428. | Read article | TheraSorb - Ig omni

  • Immunoadsorption and covid 19 pandemic
    Tseke, P. et al. (2022) Transfus. Apher. Sci. 61: 103599. | Read article | Therasorb adsorber generation not mentioned

Neurology

Reviews, single center case series

  • Plasma exchange or immunoadsorption in demyelinating diseases: a meta-analysis
    Lipphardt, M. et al. (2020) J. Clin. Med. 9: 1597 | Read article | Therasorb adsorber generation not mentioned

  • Immunoadsorption with regenerating systems in neurological disorders – A single center experience
    Hohenstein, B. et al. (2015) Atheroscler Suppl. 18: 119–123. | Read article | TheraSorb - Ig flex

  • Extracorporeal antibody elimination in neuroimmunological diseases
    Toepfer, M. et al. (1999) Ther. Apher. 3: 268–270. | Read article | Ig - TheraSorb

Multiple sclerosis, isolated syndrome, neuromyelitis optica spectrum disorders

  • Immunoadsorption in patients with multiple sclerosis: an open-label pilot study
    Moldenhauer, A. et al. (2005) Eur J. Clin. Invest. 35: 523–530. | Read article | Ig - TheraSorb

Myasthenia gravis

  • Long-term treatment of refractory myasthenia gravis with immunoadsorption
    Wagner, S. et al. (2008) Dtsch. Med. Wochenschr. 133: 2377–82. | Read article | Ig - TheraSorb

  • Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis
    Zeitler, H. et al. (2006) Artif. Organs. 30: 597–605. | Read article | Ig - TheraSorb

Other neurological diseases

  • Immunoadsorption for the treatment of narcolepsy with cataplexy
    Pincherle, A. et al. (2008) Neurol. Sci. 29: 499–500. | Read article | Ig - TheraSorb

  • Successful management of polyneuropathy associated with IgM gammopathy of undetermined significance with antibody-based immunoadsorption
    Toepfer, M. et al. (2000) Clin. Nephrol. 53: 404–407. | Read article | Ig - TheraSorb

  • Immunoadsorption in multifocal motor neuropathy
    Finsterer, J. et al. (1999) J. Immunother. 22: 441–442. | Read article | Ig - TheraSorb

Transplantation

Kidney transplantation

Antibody-mediated rejection, desensitization in kidney transplantation

  • Low incidence of acute antibody-mediated rejection after HLA desensitization in living donor kidney transplant recipients
    Fernández Rivera, C. et al. (2022) Life 12: 1993. | Read article | TheraSorb adsorber generation not mentioned

  • Successful use of nonantigen-specific immunoadsorption with antihuman Ig-columns in kidney graft antibody-mediated rejection
    Montagud-Marrahi, E. et al. (2020) J. Clin. Apher. 35: 188–199. | Read article | TheraSorb - Ig flex

  • Recent developments in desensitization of crossmatch-positive kidney transplant recipients
    Morath, C. et al. (2012) Transplant. Proc. 44: 1648–1651 | Read article | Ig - TheraSorb

  • Clearance of C4d deposition after successful treatment of acute humoral rejection in follow-up biopsies: a report of three cases
    Koller, H. et al. (2004) . Transpl. Int. 17: 177–181. | Read article | Ig - TheraSorb


ABO-incompatible kidney transplantation

  • ABO-incompatible living-donor kidney transplantation: Study of 48 patients after desensitisation
    Fernández Rivera, C. et al. (2019) Nefrologia 39: 612–622. | Read article | TheraSorb adsorber generation not mentioned

  • Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption – a retrospective study
    Speer, C. et al. (2019) Transpl. Int. 32: 1286–1296. | Read article | TheraSorb - Ig flex, Therasorb - Ig omni 5

  • Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion
    Speer, C. et al. (2019) Atheroscler. Suppl. 40: 68–72. | Read article | TheraSorb - Ig flex, Therasorb - Ig omni 5

  • Outcomes following ABO-incompatible kidney transplantation performed after desensitization by nonantigen-specific immunoadsorption
    Becker, L. E. et al. (2015) Transplantation 99: 2364–2371. | Read article | TheraSorb Ig flex

  • ABO-incompatible cardiac transplantation in pediatric patients with high isohemagglutinin titers
    Irving, C. A. et al. (2015) J. Heart Lung Transplant. 34: 1095–1102. | Read article | TheraSorb Ig flex

  • AB0 incompatible kidney transplantation using unspecific immunoadsorption
    Hickstein, H. et al. (2014) Transfus. Apher. Sci. 50: 263–266. | Read article | Ig - TheraSorb

  • ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption
    Morath, C. et al. (2012) Transplantation 93: 827–834. | Read article | TheraSorb - Ig flex

  • ABO-incompatible kidney transplantation using regenerative selective immunoglobulin adsorption
    Teschner, S. et al. (2012) J. Clin. Apher. 27: 51–60 | Read article | TheraSorb - Ig flex

ABO-incompatible transplantation, other than kidney

ABO-incompatible lung transplantation

  • Management of an ABO-incompatible lung transplant
    Banner, N. R. et al. (2004) Am. J. Transplant. 4: 1192–1196 | Read article | Ig - TheraSorb

ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation

  • Removal of persisting isohaemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation
    Rabitsch, W. et al. (2003) Nephrol. Dial. Transplant. 18: 2405–2408. | Read article | Ig - TheraSorb

  • Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption.
    Rabitsch, W. et al. (2003) Bone Marrow Transplant. 32: 1015–1019. | Read article | Ig - TheraSorb

Heart transplantation (Antibody-mediated rejection, preformed, and de novo donor-specific and donor-unspecific antibodies)

  • Antibody-mediated rejection after cardiac transplant: Treatment with immunoadsorption, intravenous immunoglobulin, and anti-thymocyte globulin
    Sipahi, N. F. et al. (2019) Int. J. Artif. Organs. 42: 370–373 | Read article | TheraSorb adsorber generation not mentioned

  • Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review
    Kaczmarek, I. et al.(2007) J. Heart Lung Transplant. 26: 511–515. | Read article | Ig - TheraSorb

Xenotransplantation

  • Ig-Therasorb immunoapheresis in orthotopic xenotransplantation of baboons with landrace pig hearts
    Brenner, P. et al. (2000) 69: 208–214. | Read article | Ig - TheraSorb

  • Prevention of hyperacute xenograft rejection in orthotopic xenotransplantation of pig hearts into baboons using immunoadsorption of antibodies and complement factors
    Brenner, P. et al. (2000) Transpl. Int. 13: S508–517. | Read article | Ig - TheraSorb

  • Influence of ischemic time on hyperacute xenograft rejection of pig hearts in a working heart perfusion model with human blood
    Brenner, P. et al. (2000) Transpl. Int. 13: S494–503. | Read article | Ig - TheraSorb

  • Effects of prolonged cold storage time in xenotransplantation
    Brenner, P. et al. (1999) J. Heart Lung Transplant. 18: 1211–1207. | Read article | Ig - TheraSorb

  • The influence of antibody and complement removal with a Ig-Therasorb column in a xenogeneic working heart model
    Brenner, P. et al. (1999), Eur. J. Cardiothorac Surg. 15: 672–679. | Read article | Ig - TheraSorb

  • Impact of immunoadsorption on xenogeneic extracorporeal pig liver perfusion: assessment of organ function during autologous reperfusion
    Kornberg, A. et al. (1999) Xenotransplantation 6: 187–193. | Read article | Ig - TheraSorb

  • The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants
    Lin, S. S. et al. (1998) J. Clin. Invest. 101: 1745–1756. | Read article | Ig - TheraSorb

  • Application of immunoapheresis for delaying hyperacute rejection during isolated xenogeneic pig liver perfusion
    Pascher, A. et al. (1997) Transplantation 63: 867–875. | Read article | Ig - TheraSorb

  • Immunoapheresis, an advanced technique for depleting human anti-porcine antibodies, delays hyperacute rejection of xenogeneic perfused pig livers
    Pascher, A. et al.(1997) Transplant. Proc. 29: 962–963. | Read article | Ig - TheraSorb

  • Fluorescence videomicroscopic assessment of xenogeneic microcirculation and impact of antibody removal by immunoadsorption
    Seehofer, D. et al. (1997) Transplantation 63: 460–465. | Read article | Ig - TheraSorb

  • Antibody removal by column immunoabsorption prevents tissue injury in an ex vivo model of pig-to-human xenograft hyperacute rejection
    Kroshus, T. J. et al. (1995) J. Surg. Res. 59: 43–50. | Read article | Ig - TheraSorb

  • Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies
    Leventhal, J. R. et al. (1995) Transplantation 59: 294–300. | Read article | Ig - TheraSorb

Nephrology

Kidney transplantation

Focal segmental glomerulosclerosis

  • Extracorporeal therapies in the treatment of focal segmental glomerulosclerosis
    Raina, R. et al. (2020) Blood Purif. 49: 513–523. | Read article | Ig - TheraSorb

  • Efficacy of the combination of immunoadsorption and rituximab for treatment in a case of severe focal and segmental glomerulosclerosis recurrence after renal transplantation
    Martin-Moreno, P. L. et al. (2018) Blood Purif. 46: 90–93. | Read article | Ig - TheraSorb

  • Remission of proteinuria in multidrug-resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption
    Nattes, E. et al. (2018) Acta Paediatr.108: 757–762. | Read article | TheraSorb adsorber generation not mentioned

  • Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre French cohort
    Allard, L. et al. (2017) Nephrol. Dial. Transplant. 33: 954–963. | Read article | TheraSorb - Ig flex

  • Immunoadsorption as a long-term therapy in recurrent focal segmental glomerulosclerosis after renal transplantation
    Frimmel, S. et al. (2017) Ther. Apher. Dial. 21: 108–109. | Read article | Ig - TheraSorb

  • Eluate derived by extracorporal antibody-based immunoadsorption elevates the cytosolic Ca2+concentration in podocytes via B2 kinin receptors
    Fischer, K. G. et al. (2002). Kidney Blood Press. Res. 25: 384–393. | Read article | Ig - TheraSorb

  • Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome
    Dantal, J. et al. (1998) J. Am. Soc. Nephrol. 9: 1709–1715. | Read article | Ig - TheraSorb


Anti-GBM disease

  • Successful pregnancy in a patient with pulmonary renal syndrome double-positive for anti-GBM antibodies and p-ANCA
    Sprenger-Mähr, H. Z. et al. (2019) Clin. Nephrol. 91: 101–106. | Read article | TheraSorb - Ig flex

  • Immunoadsorption in anti-GBM glomerulonephritis: case report in a child and literature
    Dorval, G. et al. (2017) Pediatrics 140: e20161733. | Read article | TheraSorb - Ig flex

  • Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption
    Biesenbach, P. et al. (2014) PLoS One. 9: e103568. | Read article | TheraSorb adsorber generation not mentioned

  • Immunoadsorption in Goodpasture's syndrome
    Laczika, K. et al. (2000) Am. J. Kidney Dis. 36: 392–395. | Read article | Ig - TheraSorb

  • Complete recovery of renal function in a dialysis-dependent patient with Goodpasture syndrome
    Schindler, R. et al. (1998) Nephrol. Dial. Transplant 13: 462–466. | Read article | Ig - TheraSorb

Connective tissue disease / Vasculitis

Systemic lupus erythematosus

  • Immunoadsorption: a new strategy to induce remission in membranous lupus nephritis
    Ulinski, T. et al. (2014) Case Rep. Nephrol. Urol. 4: 37–41. | Read article | TheraSorb - Ig flex

  • Immunoadsorption for connective tissue disease
    Hohenstein, B. et al. (2013) Atheroscler. Suppl. 14: 185–189. | Read article | Ig - TheraSorb

  • Immunoadsorption in SLE: Three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity
    Biesenbach, P. et al. (2009) Atheroscler. Suppl. 10: 114–121. | Read article | Ig - TheraSorb

  • Immunoadsorption for systemic lupus erythematosus
    Stummvoll, G. H. et al. (2009) Atheroscler. Suppl. 10: 110–113. | Read article | Ig - TheraSorb

  • The course of anticardiolipin antibody levels under immunoadsorption therapy
    Hauser, A. C. et al. (2005) Am. J. Kidney Dis. 46: 446–454. | Read article | Ig - TheraSorb

  • IgG immunoadsorption (IAS) reduces SLE activity and proteinuria - a long term observational study
    Stummvoll, G. H. et al. (2005) Ann. Rheum. Dis. 64: 1015–1021. | Read article | Ig - TheraSorb

  • Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy
    Stummvoll, G. H. et al. (2004) Wien Klin. Wochenschr. 116: 716–724. | Read article | Ig - TheraSorb

  • Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report
    Brunner, M. et al., (2002) Arthritis Rheum. 46: 1580–1584. | Read article | Ig - TheraSorb

  • Immunoadsorption therapy (Therasorb) in patients with severe lupus erythematosus
    Graninger, M. et al. (2002) Acta Med. Austriaca 29: 26–29. | Read article | Ig - TheraSorb

  • Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis
    Schmaldienst, S. et al. (2002) Am. J. Kidney Dis. 39: 415–418. | Read article | Ig - TheraSorb

  • Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus
    Gaubitz, M. et al. (1998) J. Autoimmun. 11: 495–501. | Read article | Ig - TheraSorb

Sjögren's syndrome

  • Identification and management of fetuses at risk for, or affected by, congenital heart block associated with autoantibodies to SSA (Ro), SSB (La), or an HsEg5-like autoantigen
    Claus, R. et al. (2006) Rheumatol. Int. 26: 886–895. | Read article | Ig - TheraSorb

  • Autoimmune-associated congenital heart block: treatment of the mother with immunoadsorption
    Hickstein, H. et al. (2005) Ther. Apher. Dial. 9: 148–153. | Read article | Ig - TheraSorb

  • Longlasting effects of immunoadsorption in severe Sjögren's syndrome
    Böhm, M. et al. (2004) Ann. Rheum. Dis. 63: 214–215. | Read article | Ig - TheraSorb

Granulomatosis with polyangiitis (Wegener's granulomatosis)

  • Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment
    Matic, G. et al. (2001) Ther. Apher. 5: 68–72. | Read article | | Ig - TheraSorb

Antiphospholipid syndrome

  • Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study
    Ruffatti, A. et al. (2016) J. Reprod. Immunol. 115: 14–19. | Read article | TheraSorb adsorber generation not mentioned

  • Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block
    Ruffatti, A. et al. (2015) Transfus. Apher. Sci. 53: 269–278. | Read article | TheraSorb adsorber generation not mentioned

Thrombangiitis obliterans

  • Immunoadsorption in thrombangiitis obliterans - a promising therapeutic option. Results of a consecutive patient cohort treated in clinical routine care
    Klein-Weigel, P. et al. (2012) Zentralbl. Chir. 137:460–465. | Read article | TheraSorb - Ig flex

  • Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study
    Baumann, G. et al. (2011) Clin. Res. Cardiol. 100: 683–690. | Read article | | Ig - TheraSorb

Dermatology

Autoimmune blistering skin disease

Pemphigus vularis, pemphigus foliaceus, pemphigoid gestationis

  • Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris
    Dietze, J. et al. (2017) Atheroscler. Suppl. 30: 271–277. | Read article | Ig - TheraSorb

  • A case of pemphigus foliaceus successfully treated with anti-Ig-Ab immunoadsorption
    Saraceno, R. et al. (2013) Transfus. Apher. Sci. 49: 87–89. | Read article | Ig - TheraSorb

  • Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis
    Marker, M. et al. (2011) J. Dtsch. Dermatol. Ges. 9: 27–31. | Read article | Ig - TheraSorb

  • Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber
    Günther, C. et al. (2008) J. Dtsch. Dermatol. Ges.6: 661–663. | Read article | Ig - TheraSorb

  • Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases
    Zillikens, D. et al. (2007) J. Dtsch. Dermatol. Ges. 5: 881–887. | Read article | Ig - TheraSorb

Paraneoplastic pemphigus

  • Immunoapheresis in paraneoplastic pemphigus
    Schoen, H. et al. (1998) Arch. Dermatol. 134: 706–710. | Read article | Ig - TheraSorb

Atopic dermatitis

  • Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis
    Reich, K. et al. (2016) J. Allergy Clin. Immunol. 137: 1882–1884. | Read article | TheraSorb Ig flex

  • Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab
    Zink, A. et al. (2016) Acta Derm. Venereol. 96: 72–76. | Read article | TheraSorb - Ig flex

  • Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis
    Daeschlein, G. et al. (2015) Ther. Apher. Dial. 19: 279–287. | Read article | TheraSorb Ig flex

  • Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study
    Kasperkiewicz, M. et al. (2011) J. Allergy Clin. Immunol. 127: 267–270. | Read article | Ig - TheraSorb

Cardiology

Dilated cardiomyopathy

  • Immunoadsorption treatment for dilated cardiomyopathy: A PRISMA-compliant systematic review and meta-analysis
    Bian, R. T. et al. (2021) Medicine (Baltimore) 100: e26475. | Read article | TheraSorb adsorber generation not mentioned

  • Functional autoantibody diseases: Basics and treatment related to cardiomyopathies
    Becker, N.P. (2019) Front. Biosci. (Landmark Ed) 24: 48–95. | Read article | Ig - TheraSorb

  • Beta-1 adrenergic receptor antibodies in children with dilated cardiomyopathy
    Camino, M. and Morales, M.D. (2019) Front. Biosci. (Elite Ed) 11: 102–108. | Read article | TheraSorb - Ig flex

  • Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension
    Dandel, M. et al. (2013) Atheroscler. Suppl. 14: 203–211. | Read article | Ig - TheraSorb

  • Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy
    Dandel, M. et al. (2012) Eur. J. Heart Fail. 14: 1374–1388. | Read article | Ig - TheraSorb

  • Effects of antibodies obtained from patients with dilated cardiomyopathy on the function of isolated rat hearts
    Staudt, Y. et al. (2006) Eur. J. Clin. Invest. 36: 85–90. | Read article | Ig - TheraSorb

  • Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy.
    Staudt, A. et al. (2006) Ther. Apher. Dial. 10: 42–48. | Read article | TheraSorb adsorber generation not mentioned

  • Effects of immunoglobulin G from patients with dilated cardiomyopathy on rat cardiomyocytes
    Christ, T. et al. (2005) Basic Clin. Pharmacol. Toxicol. 96:445–452. | Read article | Ig - TheraSorb

  • Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up
    Dörffel, W. V. et al. (2004) Int. J. Cardiol. 97: 529–534. | Read article | Ig - TheraSorb

  • Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy
    Hessel, F. P. et al. (2004) Eur. J. Health Econ. 5: 58–63. | Read article | Ig - TheraSorb

  • Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy
    Knebel, F. et al. (2004) Int. J. Cardiol. 97: 517–520. | Read article | Ig - TheraSorb

  • Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy
    Staudt, A. et al. (2004) J. Am. Coll. Cardiol. 44: 829–836. | Read article | Ig - TheraSorb

  • Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy
    Mobini, R. et al. (2003) J. Autoimmun. 20: 345–350. | Read article | Ig - TheraSorb

  • Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption
    Felix, S. B. et al. (2002) J. Am. Coll. Cardiol. 39: 645–652. | Read article | Ig - TheraSorb

  • Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy
    Staudt, A. et al. (2002) Circulation 106: 2448–2453.| Read article | Ig - TheraSorb

  • Acute hemodynamic effects during immunoadsorption in patients with dilated cardiomyopathy positive for beta 1-adrenoceptor autoantibodies
    Christ, T. et al. (2001) Methods Find. Exp. Clin. Pharmacol. 23: 141–144. | Read article | Ig - TheraSorb

  • Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption
    Schimke, I. et al. (2001) J. Am. Coll. Cardiol. 38:. 178–183. | Read article | Ig - TheraSorb

  • Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution
    Staudt, A. et al. (2001) Circulation 103: 2681–2686. | Read article | Ig - TheraSorb

  • Immunoadsorption in dilated cardiomyopathy
    Dörffel, W. V. et al. (2000) Ther. Apher. 4: 235–238. | Read article | Ig - TheraSorb

  • Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study
    Felix, S. B. et al. (2000) J. Am. Coll. Cardiol. 35: 1590–1598. | Read article | Ig - TheraSorb

  • Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy
    Müller, J. et al. (2000) Circulation 101 : 385–391. | Read article | Ig - TheraSorb

  • Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy
    Dörffel, W. V. et al. (1997) Circulation 95: 1994–1997. | Read article| Ig - TheraSorb

  • Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption
    Wallukat, G. et al. (1996) Int. J. Cardiol. 54: 191–195. | Read article | Ig - TheraSorb

Pulmonary arterial hypertension

  • Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with severe idiopathic pulmonary arterial hypertension
    Nagel, C. et al. (2017) Respiration 94: 263–271. | Read article | TheraSorb - Ig flex

  • Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension
    Dandel, M. et al. (2013) Atheroscler. Suppl. 14: 203–211. | Read article | Ig - TheraSorb

Hematology

Inhibitors against coagulation factors

  • Immunoadsorption for the treatment of acquired hemophilia: new observational data, systematic review, and meta- analysis
    Esteves Pereira, M. et al. (2021) Transfus. Med. Rev. 35: 125–134. | Read article | Ig - TheraSorb

  • Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?
    Goldmann, G. et al. (2015) Atheroscler. Suppl. 18: 74–79. | Read article | TheraSorb adsorber generation not mentioned

  • Immunoadsorption for pregnancy-associated severe acquired hemophilia
    Zeitler, H. et al. (2014) Ther. Apher. Dial. 2014 18: 103–110. | Read article | Ig - TheraSorb

  • Extracorporeal treatment for the acute und long-term outcome of patients with life-threatening acquired hemophilia
    Zeitler, H. et al. (2012) Transfus. Med. Hemother. 39: 264–270. | Read article | Ig - TheraSorb

  • The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients
    Zeitler, H. et al. (2010) Haemophilia 16: 95–101. | Read article | Ig - TheraSorb

  • Immunoadsorption in the treatment of acquired haemophilia
    Zeitler, H. et al. (2009) Atheroscler. Suppl. 10: 122–125. | Read article | Ig - TheraSorb

  • The modified Bonn Malmo protocol (MBMP) in the treatment of acquired haemophilia A
    Zeitler, H. et al. (2006) Dtsch. Med. Wochenschr. 131: 141–147. | Read article | Ig - TheraSorb

  • Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety
    von Depka, M. (2005) Haemophilia 11: 18–23. | Read article | Ig - TheraSorb

  • Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in-vivo immunomodulating concept
    Zeitler, H. et al. (2005) Blood105: 2287–2293 | Read article | Ig - TheraSorb

  • Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven®): a single centre experience
    Habermann, B. et al. (2004) Haemophilia 10: 705–712. | Read article | Ig - TheraSorb

  • Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb)
    Jansen, M. et al. (2001) Br. J. Haematol. 112: 91–97. | Read article | Ig - TheraSorb

  • Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX
    Knöbl, P. et al. (1999) Vox. Sang. 77: 57–64. | Read article | Ig - TheraSorb

  • Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy
    Toepfer, M. et al. (1998) Thromb. Haemost. 80: 1035–1036. | Read article | Ig - TheraSorb

  • Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb)
    Knöbl, P. et al. (1995) Thromb. Haemost. 74: 1035–1038. | Read article | Ig - TheraSorb

  • Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression
    Tribl, B. et al. (1995) Ann. Hematol. 71: 199–203. | Read article | Ig - TheraSorb

Evans syndrome

  • Immune thrombocytopenia, anemia and leukopenia during pregnancy. Successful therapy with extracorporeal immunoadsorption
    Julius, U. et al. (1997) Dtsch. Med. Wochenschr. 122: 220–224. | Read article | Ig - TheraSorb

Thrombotic thrombocytopenic purpura (TTP) / Immune thrombocytopenic purpura (ITP)

  • Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13
    Knöbl, P. et al. (2003) J. Thromb. Haemost. 1: 187–189. | Read article | Ig - TheraSorb

Hemolytic uremic syndrome

  • Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial
    Greinacher, A. et al. (2011) Lancet. 378: 1166–1173. | Read article | Ig - TheraSorb

Rh alloimmunization during pregnancy

  • Personalized treatment with immunoadsorption and intravenous immunoglobulin in a case of severe Rh alloimmunization during pregnancy unresponsive to plasma-exchange
    Colpo, A. et al. (2017) Transufs. Apher. Sci. 56: 480–483; | Read article | Ig - TheraSorb

Miscellaneous other indications

Autoantibodies against adeno-asscociated virus

  • Efficient removal of antibodies to adeno-associated viruses by immunoadsorption
    Boedecker-Lips, S. et al. (2023) . J. Clin. Apher. 38: 590–601. | Read article | TheraSorb - Ig omni 5

  • Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates
    Salas, D. et al. (2019) Blood Adv. 3: 2632–2641. | Read article | TheraSorb - Ig flex

Diabetes mellitus

  • Course of islet autoantibody titers during Ig-immunoadsorption in a patient with newly diagnosed type 1 diabetes
    Seidel, D. K. et al. (1998) J. Autoimmun. 11: 273–277. | Read article | Ig - TheraSorb

  • Elimination of islet cell antibodies and glutamic acid decarboxylase antibodies II in a patient with newly diagnosed insulin-dependent diabetes mellitus
    Richter, W.O. et al. (1997) J. Clin. Apheresis 12: 196–199. | Read article | Ig - TheraSorb

Endocrine ophthalmopathy

  • Two cases of refractory endocrine ophthalmopathy successfully treated with extracorporeal immunoadsorption
    Prophet, H. et al. (2001) Ther. Apher. 5: 142–146. | Read article | Ig - TheraSorb

Auto-antibody induced bile salt export pump deficiency after liver transplantion for progressive familial intrahepatic cholestasis type 2

  • Successful treatment with rituximab and immunoadsorption for an auto-antibody induced bile salt export pump deficiency in a liver transplanted patient
    Quintero, J. et al. (2020) Pediatr. Gastroenterol. Hepatol. Nutr. 23: 174–179. | Read article | TheraSorb adsorber generation not mentioned

Multiple myeloma

  • Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma - A case report
    Gauckler, P. et al. (2020) J. Clin. Apher. 35: 227–230. | Read article | TheraSorb - Ig omni

IgA nephropathy

  • Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case
    Cambier, A et al. (2022) Pediatr. Nephrol. 37: 1597–1603. | Read article | TheraSorb adsorber generation not mentioned

You have previously chosen International as your location.
What do you want to do?

Attention

The medical device and therapy related information on this website is intended for access by healthcare professionals only and their request.

The product related information on the websites covers – unless explicitly stated otherwise – only CE marked products which are marketable in the European Union. Please note that not all products and services described on the following website are cleared or available for sale in all countries. Please check the relevant country website for details.

By clicking "Accept" you are confirming that you are a healthcare professional and have read and agreed to the information above. If you are not a healthcare professional, please

click here

to be redirected to www.miltenyibiotec.com.